Glaukos Corporation is a medical instruments & supplies business based in the US. Glaukos Corporation shares (GKOS) are listed on the NYSE and all prices are listed in US Dollars. Glaukos Corporation employs 653 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Glaukos Corporation
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GKOS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Glaukos Corporation stock price (NYSE: GKOS)Use our graph to track the performance of GKOS stocks over time.
Glaukos Corporation shares at a glance
|Latest market close||$73.58|
|52-week range||$39.60 - $99.00|
|50-day moving average||$75.91|
|200-day moving average||$83.31|
|Wall St. target price||$89.44|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.37|
Buy Glaukos Corporation shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Glaukos Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Glaukos Corporation price performance over time
|1 week (2021-07-16)||N/A|
|1 month (2021-06-25)||-14.69%|
|3 months (2021-04-27)||-23.35%|
|6 months (2021-01-23)||N/A|
|1 year (2020-07-23)||N/A|
|2 years (2019-07-23)||N/A|
|3 years (2018-07-23)||N/A|
|5 years (2016-07-23)||N/A|
Is Glaukos Corporation under- or over-valued?
Valuing Glaukos Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Glaukos Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Glaukos Corporation's PEG ratio
Glaukos Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Glaukos Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Glaukos Corporation financials
|Revenue TTM||$237.6 million|
|Gross profit TTM||$158 million|
|Return on assets TTM||-4.7%|
|Return on equity TTM||-13.45%|
|Market capitalisation||$2.3 billion|
TTM: trailing 12 months
Shorting Glaukos Corporation shares
There are currently 3.8 million Glaukos Corporation shares held short by investors – that's known as Glaukos Corporation's "short interest". This figure is 1% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting Glaukos Corporation shares can be evaluated.
Glaukos Corporation's "short interest ratio" (SIR)
Glaukos Corporation's "short interest ratio" (SIR) is the quantity of Glaukos Corporation shares currently shorted divided by the average quantity of Glaukos Corporation shares traded daily (recently around 287096.18611747). Glaukos Corporation's SIR currently stands at 13.11. In other words for every 100,000 Glaukos Corporation shares traded daily on the market, roughly 13110 shares are currently held short.
However Glaukos Corporation's short interest can also be evaluated against the total number of Glaukos Corporation shares, or, against the total number of tradable Glaukos Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Glaukos Corporation's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Glaukos Corporation shares in existence, roughly 80 shares are currently held short) or 0.0839% of the tradable shares (for every 100,000 tradable Glaukos Corporation shares, roughly 84 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Glaukos Corporation.
Find out more about how you can short Glaukos Corporation stock.
Glaukos Corporation share dividends
We're not expecting Glaukos Corporation to pay a dividend over the next 12 months.
Glaukos Corporation share price volatility
Over the last 12 months, Glaukos Corporation's shares have ranged in value from as little as $39.6 up to $99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Glaukos Corporation's is 1.7399. This would suggest that Glaukos Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Glaukos Corporation overview
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. .
Stocks similar to Glaukos Corporation
Glaukos Corporation in the news
Fly Intel: Top five analyst downgrades
Glaukos downgraded to Equal Weight from Overweight at Stephens
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
Frequently asked questionsWhat percentage of Glaukos Corporation is owned by insiders or institutions?
Currently 3.251% of Glaukos Corporation shares are held by insiders and 110.666% by institutions. How many people work for Glaukos Corporation?
Latest data suggests 653 work at Glaukos Corporation. When does the fiscal year end for Glaukos Corporation?
Glaukos Corporation's fiscal year ends in December. Where is Glaukos Corporation based?
Glaukos Corporation's address is: 229 Avenida Fabricante, San Clemente, CA, United States, 92672 What is Glaukos Corporation's ISIN number?
Glaukos Corporation's international securities identification number is: US3773221029 What is Glaukos Corporation's CUSIP number?
Glaukos Corporation's Committee on Uniform Securities Identification Procedures number is: 377322102
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert